Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ALMS with free AI briefings, catalyst countdowns, and dilution alerts.

ALMS · ALUMIS INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$431.3M Cash on Hand
16.1mo Cash Runway
Follow ALMS by email Get an email when ALMS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ALMS, unsubscribe in one click. Privacy

📣 What ALMS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Blinded Envudeucitinib Plaque Psoriasis Phase 3 · NCT06846541 Active not recruiting
Envudeucitinib Plaque Psoriasis Phase 3 · NCT06588738 Completed
Open-Label Envudeucitinib Plaque Psoriasis Phase 3 · NCT06846541 Active not recruiting
ESK-001 Plaque Psoriasis Phase 2 · NCT05600036 Completed
A-005 Healthy Volunteer Phase 1 · NCT07442149 Completed
Experimental drug: ESK-001 Safety and Tolerability Phase 1 · NCT05431634 Completed
Moxifloxacin Healthy Volunteer Phase 1 · NCT07378579 Completed
Rabeprazole Pharmacokinetics Phase 1 · NCT05330858 Completed

Also used in these trials (approved or third-party drugs, not ALMS's own candidates): Apremilast.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ALMS holds $431.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $80.5M/quarter from operations, an estimated runway of 16.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 43 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ALMS files for a raise →

Get the full ALMS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ALMS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.